Xenon Pharmaceuticals (XENE) Return on Sales (2013 - 2025)

Xenon Pharmaceuticals (XENE) posted quarterly Return on Sales of 0.47% for Q4 2025, down 15.98% quarter-over-quarter from 0.41% in Q3 2025.

Xenon Pharmaceuticals (XENE) Return on Sales (2013 - 2025) Analysis & Trends

Xenon Pharmaceuticals (XENE) has reported Return on Sales for 11 consecutive years, with 0.47% the latest figure, recorded in Q4 2025.

In Q4 2025, Return on Sales changed N/A year-over-year to 0.47%; the TTM figure through Dec 2025 stood at 0.47% (changed N/A YoY), while the FY2025 annual figure was 0.47%, changed N/A from the prior year.
Return on Sales fell to 0.47% in Q4 2025 per XENE's latest filing, from 0.41% in the prior quarter.
Across five years, Return on Sales topped out at 0.02% in Q3 2021 and bottomed at 15.08% in Q2 2024.
Historically, Return on Sales has averaged 1.64% across 4 years, with a median of 0.25% in 2022.
Annual changes were most pronounced in 2022 — Return on Sales sank 280 bps — and 2025, when it jumped 1471 bps.
Xenon Pharmaceuticals' Return on Sales stood at 0.07% in 2021, then tumbled by 80 bps to 0.13% in 2022, then sank by 11244 bps to 15.08% in 2024, then jumped by 97 bps to 0.47% in 2025.
Business Quant data shows XENE's Return on Sales at 0.47% in Q4 2025, 0.41% in Q3 2025, and 0.37% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	0.00%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Xenon Pharmaceuticals	6.03 Bn	6.03 Bn	-	-

Download Data